MadeleineDuvicMD

Geriatrics • Houston, TX

Dermatologic Oncology - MD Anderson Cancer Center

Join to view full profile

Dr. Duvic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Duvic's full profile

Already have an account?

Office
6655 Travis St
600
Houston, TX 77030
Phone+1 713-500-8260

Fax+1 713-524-3432

Education & Training

Duke University HospitalFellowship, Geriatric Medicine (Internal Medicine), 1982 - 1984
Duke University HospitalResidency, Dermatology, 1978 - 1982
Duke University HospitalInternship, Internal Medicine, 1977 - 1978
Duke University School of MedicineClass of 1977

Certifications & Licensure

TX State Medical License 1984 - 2025
OK State Medical License 2020 - 2021
NC State Medical License 1977 - 2004
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology
Join now to see all

Clinical Trials

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Start of enrollment: 2003 May 01
Completed
Phase 2, Phase 3
Alopecia Areata Registry Start of enrollment: 2001 Nov 01
Active, not recruiting
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Start of enrollment: 2004 Apr 02
Completed
Phase 4
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Melanoma Detection by Oblique-Incidence Optical Spectroscopy Start of enrollment: 2006 Sep 01
Completed
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2008 Jan 01
Completed
Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Start of enrollment: 2012 Nov 01
Withdrawn
Phase 2
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2013 Feb 01
Completed
Phase 1
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Start of enrollment: 2015 Sep 01
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

184 citations
Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-ce...
Anita G. Seto, Xuan Beatty, Joshua M. Lynch, Melanie Hermreck, Michael T. Tetzlaff
British Journal of Haematology. 2018-08-20
139 citations
Guidelines of care for the management of primary cutaneous melanoma.
Susan M Swetter, Hensin Tsao, Christopher K Bichakjian, Clara Curiel-Lewandrowski, David E Elder
Journal of the American Academy of Dermatology. 2019-01-01
754 citations
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss
Journal of Clinical Oncology. 2007-07-20

Journal Articles

Cobomarsen, an Oligonucleotide Inhibitor of miR‐155, Co‐Ordinately Regulates Multiple Survival Pathways to Reduce Cellular Proliferation and Survival in Cutaneous T‐Ce...
Madeleine Duvic, Michael Tetzlaff, British Journal of Haematology

Abstracts/Posters

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Madeline Duvic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
Madeleine Duvic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Management Issues in Cutaneous Lymphoma
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2017May 15th, 2017
Moleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016April 3rd, 2017
Moleculin Announces Expanded Scientific Advisory BoardJanuary 19th, 2017
Join now to see all

Grant Support

Cutaneous OncologyNational Cancer Institute2000–2004
Alopecia Areata RegistryNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000
Markers Of Response In Cutaneous T-Cell LymphomaNational Cancer Institute1998–1999
Third International Research Workshop--Alopecia AreataNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1998
Pathogenesis And Treatment Of Hiv-Associated PsoriasisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1993–1995
Selective Manipulation Of Gene Expression In SkinNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1990–1992
Genetic Heterogeneity: Ehlers Danlos Syndromes VII &IvEunice Kennedy Shriver National Institute Of Child Health &Human Development1990–1992
Pathogenesis Of AIDS/HIV Associated PsoriasisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1989–1991
Isolation Of Pemphigus Antigen CDNANational Institute Of Arthritis And Musculoskeletal And Skin Diseases1986–1990

Professional Memberships

American Academy of Dermatology - AAD
Fellow